Update: Partial Clinical Hold Lifted by FDA for GSK2402968 (Exon 51 Skip)

Update: Partial Clinical Hold Lifted by FDA for GSK2402968 (Exon 51 Skip): "GlaxoSmithKline (GSK) has provided an update regarding the clinical development program for GSK2402968 (exon 51 skip) for DMD: The US Food and Drug Administration has lifted the partial clinical hold on the Investigational New Drug Application for GSK2402968. This means GSK can now proceed with longer term clinical studies of GSK2402968 in DMD patients in the US."

ACE-031 statement from Acceleron and Shire - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

ACE-031 statement from Acceleron and Shire - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "ACE-031 STATEMENT FROM ACCELERON AND SHIRE
Clinical trial suspended; intention is to start a new study after discussions with regulatory agencies"

Tweaking gene in satellite cells may increase lifespan of people with muscular dystrophy

Tweaking gene in satellite cells may increase lifespan of people with muscular dystrophy: "Tweaking gene in satellite cells may increase lifespan of people with muscular dystrophy"

Teen With Duchenne Muscular Dystrophy Keeps on Achieving - YNN, Your News Now

Teen With Duchenne Muscular Dystrophy Keeps on Achieving - YNN, Your News Now: "Teen With Duchenne Muscular Dystrophy Keeps on Achieving"

Parent Project Muscular Dystrophy: GSK 2402968 (PRO-051)

Parent Project Muscular Dystrophy: GSK 2402968 (PRO-051): "the forty-eight week follow-up data from the phase I/IIa extension study (PRO051-02) will be presented at an oral session on April 13, 2011 during the 63rd annual meeting of the American Academy of Neurology."

Run for Scotland - DeanWidd - Stopwasting - Action Duchenne - Fighting for a cure for muscular dystrophy

Run for Scotland - DeanWidd - Stopwasting - Action Duchenne - Fighting for a cure for muscular dystrophy: "If you are a runner rather than a walker then why not get involved with the 5k fun run around Holyrood Park Edinburgh on Sunday 5th June.

Starting at Holyrood Park at 9.30am runners of all abilities are welcome to get involved and help raise awareness and funds for Action Duchenne. All runners will receive a medal , completion certificate and a goody bag."

AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658 - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658 - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that the United States Adopted Names (USAN) Council has approved the nonproprietary name eteplirsen for AVI-4658, the Company's exon-skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by the absence of functional dystrophin. In addition, the World Health Organization (WHO) has approved eteplirsen as the International Nonproprietary Name (INN) for AVI-4658."